

ASX Announcement

19 November 2020

Lapse of Unlisted Share Options

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, advises that the following unlisted share options granted pursuant to Regeneus' option share trust plan have lapsed with the resignation of Leo Lee as CEO.

Lapsed Options	Exercise Price	Expiry Date
2,500,000	\$0.25	31/1/2024
3,500,000	\$0.15	1/10/2024
750,000	\$0.20	1/10/2024
750,000	\$0.25	1/10/2024
750,000	\$0.30	1/10/2024
750,000	\$0.35	1/10/2024

In addition to the share options that have lapsed as detailed above, as a result of his resignation as CEO and change from an executive to a non-executive director, Leo Lee has not, and will not be issued any of the 12,250,000 options approved by shareholders for issue to him at the 2020 AGM held on 14 October 2020.

The total number of options remaining on issue following the lapse of the above options are as follows:

Number of Options	Exercise Price	Expiry Date
1,250,000	\$0.20	31/1/2024
1,000,000	\$0.10	30/09/2024
2,980,770	\$0.10	30/06/2025
1,029,500	\$0.14	31/08/2025
2,000,000	\$0.1075	31/08/2025

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by
the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications

T: 02 9237 2805

E: WE-AURegeneus@we-worldwide.com